|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||June 01, 2018|
|Effective date (End):||May 31, 2019|
|Field of knowledge:||Agronomical Sciences - Veterinary Medicine - Animal Pathology|
|Principal Investigator:||Sérgio Luis Felisbino|
|Grantee:||Teng Fwu Shing|
|Home Institution:||Instituto de Biociências (IBB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil|
Prostate lesions in dogs have been increasingly studied, since this species is used as an experimental model for prostatic disease in man. The most common lesions affecting dog prostate are benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), proliferative inflammatory atrophy (PIA) and adenocarcinoma. Oxidative stress is an important factor for the development and progression of cancer, since cancer cells are in high metabolic activity. Some studies have demonstrated an increase in the expression of oxidative stress enzymes, such as sulphirdoxin, in tumor cells of various organs and tissues in humans, mainly. Sulfiredoxin participates in the recycling pathway of peroxiredoxins 1-4, protecting the cells from entering the process of apoptosis due oxidative stress, sustaining cancer cells growth and progression. This work aims to evaluate the levels of tissue protein expression of sulfiredoxin in canine prostate samples containing prostatic affections and to correlate them with tumor staging data. To do this, dog prostates provided by Dr. Renee Laufer Amorim, a pathologist at the Department of Veterinary Clinic of FMVZ - UNESP, Botucatu, will be used. Paraffin sections from the Department arquive will be stained by H&E for the diagnosis of the lesions and also submitted to immunohistochemistry against the enzyme sulfiredoxin. The expression pattern of sulfiredoxin will be evaluated in areas of normal prostates, and with HPB, PIN, PIA, differentiated and undifferentiated adenocarcinoma. In view of the results, sulfiredoxin may be used as a diagnostic marker for prostatic disorders in dogs, or tumor progression, or whether it may be a therapeutic target for the treatment of human and canine prostate cancer.